PROP1 and CTNNB1 expression in adamantinomatous craniopharyngiomas with or without beta-catenin mutations

Imagem de Miniatura
Arquivos
art_CANI_PROP1_and_CTNNB1_expression_in_adamantinomatous_craniopharyngiomas_with_2011.PDF (715.47 KB)
Citações na Scopus
26
Tipo de produção
article
Data de publicação
2011
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
HOSPITAL CLINICAS, UNIV SAO PAULO
Autores
CANI, Carolina M. G.
Citação
CLINICS, v.66, n.11, p.1849-1854, 2011
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
INTRODUCTION: Activating mutations in exon 3 of the beta-catenin gene are involved in the pathogenesis of adamantinomatous craniopharyngiomas. Recently, the interaction between beta-catenin and PROP1 has been shown to be responsible for pituitary cell lineage determination. We hypothesized that dysregulated PROP1 expression could also be involved in the pathogenesis of craniopharyngiomas. OBJECTIVES: To determine whether dysregulated gene expression was responsible for tumor pathogenesis in adamantinomatous craniopharyngiomas, the beta-catenin gene was screened for mutations, and the expression of the beta-catenin gene and PROP1 was evaluated. METHODS: The beta-catenin gene was amplified and sequenced from 14 samples of adamantinomatous craniopharyngiomas. PROP1 and beta-catenin gene expression was assessed by real-time RT-PCR from 12 samples, and beta-catenin immunohistochemistry was performed on 11 samples. RESULTS: Mutations in the beta-catenin gene were identified in 64% of the adamantinomatous craniopharyngiomas samples. Evidence of beta-catenin gene overexpression was found in 71% of the tumors with beta-catenin mutations and in 40% of the tumors without mutations, and beta-catenin immunohistochemistry revealed a nuclear staining pattern for each of the analyzed samples. PROP1 expression was undetectable in all of the tumor samples. CONCLUSION: We found evidence of beta-catenin gene overexpression in the majority of adamantinomatous craniopharyngiomas, and we also detected a nuclear beta-catenin staining pattern regardless of the presence of a beta-catenin gene mutation. These results suggest that WNT signaling activation plays an important role in the pathogenesis of adamantinomatous craniopharyngiomas. Additionally, this study was the first to evaluate PROP1 expression in adamantinomatous craniopharyngiomas, and the absence of PROP1 expression indicates that this gene is not involved in the pathogenesis of this tumor, at least in this cohort.
Palavras-chave
Sellar tumor, Real-time PCR, WNT pathway, Gene expression, Pituitary
URI
https://observatorio.fm.usp.br/handle/OPI/22574
Referências
  1. Abrao MG, 2006, CLIN ENDOCRINOL, V65, P294, DOI 10.1111/j.1365-2265.2006.02592.x
  2. Kato K, 2004, J PATHOL, V203, P814, DOI 10.1002/path.1562
  3. Voutetakis A, 2004, J CLIN ENDOCR METAB, V89, P2200, DOI 10.1210/jc.2003-031765
  4. Gooding JM, 2004, BIOESSAYS, V26, P497, DOI 10.1002/bies.20033
  5. Cushman LJ, 2001, HUM MOL GENET, V10, P1141, DOI 10.1093/hmg/10.11.1141
  6. TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419
  7. Turton JPG, 2005, CLIN ENDOCRINOL, V63, P10, DOI 10.1111/j.1365-2265.2005.02291.x
  8. ADAMSON TE, 1990, J NEUROSURG, V73, P12, DOI 10.3171/jns.1990.73.1.0012
  9. LI S, 1990, NATURE, V347, P528, DOI 10.1038/347528a0
  10. Kikuchi A, 2007, CELL SIGNAL, V19, P659, DOI 10.1016/j.cellsig.2006.11.001
  11. Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
  12. Jho EH, 2002, MOL CELL BIOL, V22, P1172, DOI 10.1128/MCB.22.4.1172-1183.2002
  13. Karavitaki N, 2006, ENDOCR REV, V27, P371, DOI 10.1210/er.2006-0002
  14. ASA SL, 1983, VIRCHOWS ARCH A, V399, P49
  15. Kim JS, 2002, CANCER RES, V62, P2744
  16. GOLDBERG GM, 1960, ARCH PATHOL, V70, P293
  17. Sornson MW, 1996, NATURE, V384, P327, DOI 10.1038/384327a0
  18. Buslei R, 2005, ACTA NEUROPATHOL, V109, P589, DOI 10.1007/s00401-005-1004-x
  19. Polakis P, 2000, GENE DEV, V14, P1837
  20. Oikonomou E, 2005, J NEURO-ONCOL, V73, P205, DOI 10.1007/s11060-004-5232-z
  21. Olson LE, 2006, CELL, V125, P593, DOI 10.1016/j.cell.2006.02.046
  22. Bunin GR, 1998, J NEUROSURG, V89, P547, DOI 10.3171/jns.1998.89.4.0547
  23. Zhu XY, 2007, PHYSIOL REV, V87, P933, DOI 10.1152/physrev.00006.2006
  24. Sekine S, 2002, AM J PATHOL, V161, P1997, DOI 10.1016/S0002-9440(10)64477-X
  25. Holsken A, 2008, BRAIN PATHOL, V19, P357, DOI 10.1111/j.1750-3639.2008.00180.x
  26. Hurlstone A, 2002, EMBO J, V21, P2303, DOI 10.1093/emboj/21.10.2303
  27. Mendonca BB, 1999, J CLIN ENDOCR METAB, V84, P942, DOI 10.1210/jc.84.3.942
  28. Nakayama M, 2009, MOL CELL ENDOCRINOL, V307, P36, DOI 10.1016/j.mce.2009.03.010
  29. Nascif Sergio Oliva, 2006, Pituitary, V9, P47, DOI 10.1007/s11102-006-6215-1
  30. Ohazama A, 2005, J DENT RES, V84, P603
  31. Showalter AD, 2002, GENE, V291, P211, DOI 10.1016/S0378-1119(02)00599-1
  32. Teinturier C, 2002, J PEDIATR ENDOCR MET, V15, P95
  33. Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/14
Artigos e Materiais de Revistas Científicas - LIM/42